IMV Inc. (IMV) |
| 0.8225 0 (0%) 04-28 15:58 |
| Open: | 0.811 |
| High: | 0.84 |
| Low: | 0.7753 |
| Volume: | 44,894 |
| Market Cap: | 10(M) |
| PE Ratio: | -0.18 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.46 |
| Resistance 1: | 0.28 |
| Pivot price: | 0.10 |
| Support 1: | 0.00 |
| Support 2: | 0.00 |
| 52w High: | 10.4 |
| 52w Low: | 0.0002 |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Financials
| EPS | -39580000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 49.342 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -12.00 |
| Return on Assets (ttm) | 239.2 |
| Return on Equity (ttm) | -61.8 |
Company news
Thu, 25 Sep 2025
Attack on Titan Unique Ads Appear in Osaka Station Underground: “Did That Wall Undergo a Vibration Test?” - Japan Anime News
Tue, 29 Jul 2025
QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™ - PR Newswire
Sat, 22 Mar 2025
A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression - Nature
Wed, 21 Feb 2024
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC. - PR Newswire
Tue, 13 Feb 2024
BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets - Pharmaceutical Technology
Mon, 12 Feb 2024
BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc. - Contract Pharma
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
